

October 6, 2025

The Board of Directors

Xuanzhu Biopharmaceutical Co., Ltd. 軒竹生物科技股份有限公司

2107, Building 2

Zhubang 2000 Business Center

Balizhuang Xili

Chaoyang District, Beijing

PRC

Dear Sirs/Madams,

Xuanzhu Biopharmaceutical Co., Ltd. 軒竹生物科技股份有限公司 (the “Company”)

Listing on the Main Board of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”)

We refer to the prospectus of the Company dated October 6, 2025 (the “**Prospectus**”) in connection with the proposed global offering and listing of the H shares of the Company on the Main Board of the Stock Exchange. Capitalized terms used in this letter shall have the same meaning as those which are defined in the Prospectus.

We hereby give our consent and confirm that we have not withdrawn our written consent to the issue of the Prospectus with the inclusion therein of our name, address, qualifications and opinions and all references thereto, in the form and context in which they respectively appear in the Prospectus.

We hereby consent to a copy of this letter being released to the Registrar of Companies in Hong Kong and the Stock Exchange. We also consent to a copy of this letter and our opinion referred to above being made available on display as described as described in “Documents Delivered to the Registrar of Companies and Available on Display” in Appendix VII to the Prospectus.

[The remainder of this page is intentionally left blank]

For and on behalf of:

China International Capital Corporation Hong Kong Securities Limited

By:

A handwritten signature in black ink, appearing to be 'Zhong Li', written over a horizontal line.

Name: ZHONG Li
Title: Executive Director



Ernst & Young
27/F, One Taikoo Place
979 King's Road
Quarry Bay, Hong Kong

安永會計師事務所
香港鰂魚涌英皇道 979 號
太古坊一座 27 樓

Tel 電話: +852 2846 9888
Fax 傳真: +852 2868 4432
ey.com

6 October 2025

The Board of Directors
Xuanzhu Biopharmaceutical Co., Ltd.
2107, Building 2, Zhubang 2000 Business Center, Balizhuang Xili, Chaoyang District,
Beijing
PRC

Dear Sirs,

Xuanzhu Biopharmaceutical Co., Ltd. (the "Company") and its subsidiaries (the "Group")
Listing on the Main Board of The Stock Exchange of Hong Kong Limited

We refer to the prospectus dated 6 October 2025 (the "Prospectus") in connection with the proposed initial listing of H shares of the Company on the Main Board of The Stock Exchange of Hong Kong Limited, a final proof of which is attached and initialed by us on its front cover for the purpose of identification.

We hereby consent to the inclusion of our accountants' report dated 6 October 2025 on the historical financial information for the years ended 31 December 2023, 2024 and the six months ended 30 June 2025 and our accountants' report dated 6 October 2025 on the unaudited pro forma financial information as at 30 June 2025 in the Prospectus, and the references to our name in the form and context in which they are included.

This letter is solely being issued in connection with the filing of the Prospectus regarding the listing of the Company's securities on The Stock Exchange of Hong Kong Limited and not for any other purpose.



Yours faithfully,

Certified Public Accountants
Hong Kong

方達律師事務所
FANGDA PARTNERS

北京 Beijing • 广州 Guangzhou • 香港 Hong Kong • 南京 Nanjing • 上海 Shanghai • 深圳 Shenzhen • 新加坡 Singapore

<http://www.fangdalaw.com>

中国上海市石门一路288号
兴业太古汇香港兴业中心二座24楼
邮政编码: 200041

电子邮件 E-mail: email@fangdalaw.com
电话 Tel.: +86-21-2208 1166
传真 Fax.: +86-21-5298 5599

24/F, HKRI Centre Two
HKRI Taikoo Hui
288 Shi Men Yi Road
Shanghai, PRC
200041

October 6, 2025

The Board of Directors

Xuanzhu Biopharmaceutical Co., Ltd. 軒竹生物科技股份有限公司

2107, Building 2
Zhubang 2000 Business Center
Balizhuang Xili
Chaoyang District, Beijing
PRC

Dear Sirs/Madams,

Xuanzhu Biopharmaceutical Co., Ltd. 軒竹生物科技股份有限公司 (the “Company”)

Listing on the Main Board of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”)


We refer to the prospectus of the Company dated October 6, 2025 (the “**Prospectus**”) in connection with the proposed global offering and listing of the H shares of the Company on the Main Board of the Stock Exchange. Capitalized terms used in this letter shall have the same meaning as those which are defined in the Prospectus.

We hereby give our consent and confirm that we have not withdrawn our written consent to the issue of the Prospectus with the inclusion therein of all statements issued by us, and references to statements in our name, address, qualifications and our opinions in the form and context in which they respectively appear in the Prospectus.

We hereby consent to a copy of this letter being released to the Registrar of Companies in Hong Kong and the Stock Exchange. We also consent to a copy of this letter and our opinion referred to above being made available on display as described as described in “Documents Delivered to the Registrar of Companies and Available on Display” in Appendix VII to the Prospectus.

[The remainder of this page is intentionally left blank]

Yours faithfully,
For and on behalf of
Fangda Partners)



Kang Yan
Partner

The Board of Directors

Xuanzhu Biopharmaceutical Co., Ltd. 軒竹生物科技股份有限公司

2107, Building 2
Zhubang 2000 Business Center
Balizhuang Xili
Chaoyang District, Beijing
PRC

Dear Sirs/Madams,

Xuanzhu Biopharmaceutical Co., Ltd. 軒竹生物科技股份有限公司 (the “Company”)

Listing on the Main Board of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”)


We refer to the prospectus of the Company dated October 6, 2025 (the “**Prospectus**”) in connection with the proposed global offering and listing of the H shares of the Company on the Main Board of the Stock Exchange. Capitalized terms used in this letter shall have the same meaning as those which are defined in the Prospectus.

We hereby give our consent and confirm that we have not withdrawn our written consent to the issue of the Prospectus with the inclusion therein of our name, address, qualifications and opinions and all references thereto, in the form and context in which they respectively appear in the Prospectus.

We hereby consent to a copy of this letter being released to the Registrar of Companies in Hong Kong and the Stock Exchange. We also consent to a copy of this letter and our opinion referred to above being made available on display as described as described in “Documents Delivered to the Registrar of Companies and Available on Display” in Appendix VII to the Prospectus.

[The remainder of this page is intentionally left blank]

Yours faithfully,
For and on behalf of
China Insights Industry Consultancy Limited



Glenn Hou
Founding Partner